Total Health
W

ASCO 2022 Updates in Lymphoma and CLL

By Total Health FEATURING William Hammond
By Total Health FEATURING William Hammond
0 views
August 9, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

01:29
Incyte

Targeting CSF-1R to Manage Inflammation and Fibrosis in GVHD

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Recommended

AUTOPLAY
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
12:47
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "Experts Discuss Key Abstracts in CLL"

Feat. S. O'Brien, C. Coombs
17:05
Cleveland Clinic Taussig Cancer Institute

Frontline CLL Learnings From Phase 3 RESONATE-2, iLLUMINATE, and E19…

Feat. A. Winter
24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou
06:53
UC Irvine Health

Fixed-Duration Treatment in CLL: Current Considerations

Feat. E. Brem
25:47
Massachusetts General Hospital Cancer Center

Practice-Changing Updates in Indolent B-Cell Lymphomas

Feat. J. Soumerai
24:33
Indy Hematology Review

Therapeutic Options in CLL in 2023: Choosing the Initial Therapy Wis…

Feat. J. Woyach
03:06
City of Hope

CLL Treatment Sequencing: The Importance of First Choice

Feat. S. Rosen
08:17
Adam Kittai

Highlights From iwCLL 2023: What's New and Practice Informing i…

15:21
5th SOHO Italy Annual Conference

How I Treat CLL at the MD Anderson Cancer Center

Feat. A. Ferrajoli
08:42
City of Hope

Venetoclax vs. BTKis in CLL Treatment

Feat. A. Danilov
19:14
2024 ASCO® Annual Meeting Insights Hub

Experts Discuss Highlights and Key Takeaways in CLL From ASCO® and E…

Feat. K. Rogers, J. Woyach
10:06
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Results of A041702, an Alliance Phase 3 S…

Feat. J. Woyach
15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
20:58
Andrew Lipsky

CLL: Recent Updates on the Use of BTK Inhibitors

06:21
City of Hope

Cardiac Safety of Zanubrutinib vs. Other BTKis in CLL

Feat. A. Danilov
17:21
Daniel Addison

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…

18:01
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "MRD-Directed Therapy in CLL - Ready for Pri…

Feat. J. Rhodes
23:11
Indy Hematology Review

Treatment Considerations for Initial Therapy of CLL

Feat. P. Hillmen